Earnings Per Share (EPS) matched the estimated EPS of $1.01, showcasing the company’s stable profitability.
Revenue exceeded expectations at approximately $987.9 million, indicating strong sales performance.
Financial Ratios such as the price-to-earnings (P/E) ratio of 24.79 and a current ratio of 3.69 highlight Hologic’s solid financial foundation and market valuation.
Hologic, Inc. (NASDAQ:HOLX) is a leading medical technology company specializing in women’s health. It competes with healthcare giants like Siemens Healthineers and GE Healthcare. The company’s Q4 2024 earnings report provides valuable insights into its financial health and market performance.
On November 4, 2024, Hologic reported an EPS of $1.01, aligning with the estimated EPS. The company’s revenue of approximately $987.9 million surpassed the estimated $976.69 million, demonstrating a robust sales performance. Despite this, Hologic’s EPS slightly missed the Zacks Consensus Estimate by $0.01, yet it showed improvement from the previous year’s EPS of $0.89.
The company’s market valuation is reflected in its financial metrics, with a P/E ratio of 24.79, a price-to-sales ratio of 4.83, and an enterprise value to sales ratio of 4.92. Hologic’s financial stability is further indicated by a debt-to-equity ratio of 0.49 and a current ratio of 3.69, suggesting a moderate level of debt and strong liquidity.
These financial indicators underscore Hologic’s solid foundation and potential for continued growth in the competitive healthcare sector.
